BioNTech has announced a major global restructuring initiative that will include the closure of selected operational sites in Germany and Singapore, impacting approximately 1,860 positions across its international network as the company sharpens its focus on oncology, next generation immunotherapies, and sustainable long term growth.

The strategic realignment comes as the biotechnology company adapts to changing post pandemic market dynamics and rebalances its manufacturing and operational footprint following the extraordinary scale up undertaken during the COVID 19 vaccine response. The company stated that the restructuring is designed to improve operational efficiency, streamline global manufacturing capacity, and redirect investments toward high value innovation programmes across oncology, mRNA therapeutics, and precision medicine.

As part of the transition, BioNTech will gradually wind down activities at selected facilities in Germany and Singapore over the coming phases, while consolidating resources into core research, development, and commercial hubs. The company indicated that the workforce reductions will affect a combination of manufacturing, operations, support, and administrative functions.

BioNTech noted that it will work closely with employee representatives, local authorities, and affected teams throughout the transition process, with support measures expected to include redeployment opportunities, transition assistance, and workforce support programmes where applicable.

The move reflects a broader shift taking place across the global biotechnology and pharmaceutical sector, where companies that rapidly expanded infrastructure during the pandemic are now reassessing manufacturing demand, cost structures, and long term portfolio priorities. Industry analysts expect operational consolidation and targeted restructuring activity to continue across the life sciences sector as organisations increasingly prioritise capital efficiency and specialised therapeutic pipelines.

Despite the restructuring, BioNTech reaffirmed its commitment to advancing its oncology pipeline, including personalised cancer vaccines, cell therapies, bispecific antibodies, and infectious disease programmes. The company continues to position oncology as its primary long term growth engine, with multiple late stage programmes and international collaborations currently underway.

The Singapore operations had served as part of BioNTech’s broader Asia Pacific manufacturing and strategic expansion plans. The restructuring is expected to reshape how the company approaches regional manufacturing partnerships and commercial operations in the Asia Pacific market moving forward.

BioNTech stated that additional details regarding implementation timelines, operational transitions, and future investment priorities will be communicated in accordance with local regulatory and employee consultation requirements.